Decreased All-cause and liver-related mortality risk in HIV/Hepatitis B virus coinfection coinciding with the introduction of tenofovir-containing combination antiretroviral therapy

Autor: Joop E. Arends, Berend J van Welzen, Anders Boyd, Annemarie E. Brouwer, Peter Reiss, Andy I.M. Hoepelman, Colette Smit, Faydra I Lieveld, Tania Mudrikova
Přispěvatelé: Infectious diseases, Global Health, AII - Infectious diseases, APH - Aging & Later Life, APH - Methodology, APH - Global Health
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Zdroj: Open Forum Infectious Diseases
Open forum infectious diseases, 7(7):ofaa226. Oxford University Press
ISSN: 2328-8957
DOI: 10.1093/ofid/ofaa226
Popis: Background The development of efficacious combination antiretroviral therapy (cART) has led to a dramatic decrease in mortality in HIV-positive patients. Specific data on the impact in HIV/hepatitis B virus (HBV)–coinfected patients are lacking. In this study, all-cause and cause-specific mortality risks stratified per era of diagnosis are investigated. Methods Data were analyzed from HIV/HBV-coinfected patients enrolled in the ATHENA cohort between January 1, 1998, and December 31, 2017. Risk for (cause-specific) mortality was calculated using Cox proportional hazard regression analysis, comparing patients diagnosed before 2003 with those diagnosed ≥2003. Risk factors for all-cause and liver-related mortality were also assessed using Cox proportional hazard regression analysis. Results A total of 1301 HIV/HBV-coinfected patients were included (14 882 person-years of follow-up). One-hundred ninety-eight patients (15%) died during follow-up. The adjusted hazard ratio (aHR) for all-cause mortality in patients diagnosed in or after 2003 was 0.50 (95% CI, 0.35–0.72) relative to patients diagnosed before 2003. Similar risk reduction was observed for liver-related (aHR, 0.29; 95% CI, 0.11–0.75) and AIDS-related mortality (aHR, 0.44; 95% CI, 0.22–0.87). Use of a tenofovir-containing regimen was independently associated with a reduced risk of all-cause and liver-related mortality. Prior exposure to didanosine/stavudine was strongly associated with liver-related mortality. Ten percent of the population used only lamivudine as treatment for HBV. Conclusions All-cause, liver-related, and AIDS-related mortality risk in HIV/HBV-coinfected patients has markedly decreased over the years, coinciding with the introduction of tenofovir. Tenofovir-containing regimens, in absence of major contraindications, should be strongly encouraged in this population.
This ATHENA cohort based analysis shows a decline in the risk for all-cause and liver-related mortality in patients with a HIV/Hepatitis B virus coinfection diagnosed in the tenofovir era. However, physicians should strive to maintain optimal HBV suppression.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje